Specialty Drug Approvals: 2015 Highlights + 2016 Projections
In 2015, the recent trend continued with a greater-than-average number of drug approvals compared to past years. Special FDA designations such as breakthrough, fast track, orphan, accelerated approval and priority review have been applied to promising drugs or those that treat diseases with an unmet medical need. These designations have reduced the time needed for clinical trials and/or reduced the FDA review timeline, allowing pipeline products to come to market more quickly than in the past.1
Sign up to read our White Paper and receive helpful updates from Diplomat.
1. Developing products for rare disease & conditions. U.S. Food and Drug Administration (FDA) Website. Accessed December 1, 2015.
@DiplomatRxDiplomat to Dispense DUPIXIENT® to Treat Atopic Dermatitis https://t.co/KGA2xuWm2C8 hours ago
@RGA_RERT @RGA_RE: Some trends in the #specialtypharma market: #biosimilars, coopetition, M&A, retailer buildout, limited-distro- Dr. Atheer Kaddi…5 days ago
@DiplomatRxDiplomat to Dispense KISQALI for Metastatic Breast Cancer https://t.co/zpwRxfYCwr2 weeks ago
@MSassociationRT @MSassociation: It's still #MSAwarenessMonth all March long! RT & learn how YOU can help the MS community: https://t.co/kDFYPMMUzL https…2 weeks ago
@sloan_ketteringRT @sloan_kettering: During #NationalNutritionMonth, check out 8 tips to eat right and stay at a healthy weight during and after treatment.…2 weeks ago